Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

The prognostic impact of minimal residual disease (MRD) was analyzed in 259 patients with mantle cell lymphoma (MCL) treated within two randomized trials of the European MCL Network (MCL Younger and MCL Elderly trial). After rituximab-based induction treatment 106/190 evaluable patients (56%) achiev...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Pott, Christiane, Hoster, Eva, Delfau-Larue, Marie-Hélène, Beldjord, Kheira, Böttcher, Sebastian, Asnafi, Vahid, Plonquet, Anne, Siebert, Reiner, Callet-Bauchu, Evelyne, Andersen, Niels, Van Dongen, Jacques J. M., Klapper, Wolfram, Berger, Françoise, Ribrag, Vincent, Van Hoof, Achiel L., Trneny, Marek, Walewski, Jan, Dreger, Peter, Unterhalt, Michael, Hiddemann, Wolfgang, Kneba, Michael, Kluin-Nelemans, Hanneke C., Hermine, Olivier, Macintyre, Elizabeth, Dreyling, Martin
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2010
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2930903/
https://ncbi.nlm.nih.gov/pubmed/20032498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-06-230250
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares